Beam Therapeutics (BEAM) Current Deferred Revenue (2020 - 2026)

Beam Therapeutics (BEAM) has 7 years of Current Deferred Revenue data on file, last reported at $304000.0 in Q1 2026.

• On a quarterly basis, Current Deferred Revenue fell 99.64% year-over-year to $304000.0 in Q1 2026; TTM through Mar 2026 was $304000.0, a 99.64% decrease from a year earlier, with the FY2025 full-year figure at $6.7 million, down 95.31% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $304000.0, down from $6.7 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for BEAM reached as high as $338.2 million in Q4 2022 and fell as low as $304000.0 in Q1 2026.
• Historically, Current Deferred Revenue has averaged $121.4 million across 5 years, with a median of $115.0 million in 2022.
• Across the five-year window, Current Deferred Revenue soared 1147.09% in 2022 and sank 99.64% in 2026, its largest moves.
• Year by year, Current Deferred Revenue stood at $338.2 million in 2022, then plunged by 47.19% to $178.6 million in 2023, then retreated by 20.45% to $142.1 million in 2024, then tumbled by 95.31% to $6.7 million in 2025, then tumbled by 95.43% to $304000.0 in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $304000.0 in Q1 2026, $6.7 million in Q4 2025, and $110.3 million in Q3 2025.